Latest From NephroGenex Inc.
ViGuard Health says in a petition that with two IND programs for studies of pyridoxamine's potential therapeutic use formally withdrawn, FDA should rescind its 2009 decision that it did not qualify as a dietary ingredient.
Once-prosperous biotechs are now seeking strategic alternatives including the selling off of all of their assets now that they've failed to acquire the funds they need to move forward.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2015.
The year was marked by record levels of biopharma M&A activity and a strong IPO market. Measures designed to deliver early access to new medicines continued to advance on both sides of the Atlantic, while pricing came in for renewed attention as new, highly effective but extremely expensive products reached the market.
- Therapeutic Areas
- Renal System
- North America
- Parent & Subsidiaries
- NephroGenex Inc.
- Senior Management
Pierre Legault, CEO
John P Hamill, CFO
J. Wesley Fox, PhD, Pres. & CSO
Jaikrishna Patel, MD, CMO
- Contact Info
Phone: (609) 986-1780
3200 Beechleaf Ct.
Raleigh, NC 27604
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.